Open-to-Accrual Therapeutic Trials


Phase I

Protocol ID Official Title PI Name Lead CRC Disease Site Phase
I137-102    ClinicalTrials.gov    NCT02931110 A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers C. Sportès Crystal Durden Lymphomas (B-Cell, Diffuse Large B-Cell,  Mantle Cell, Follicular, Hodgkin; Lymphosarcoma) I
NLG-2105  ClinicalTrials.gov NCT02502708 A Phase 1 Trial of Indoximod in Combination with Temozolomide-Based Therapy for Children with Progressive Primary Brain Tumors T. Johnson Robin Dobbins Primary Brain Tumors I
ONC-DPX SURVIVAC-06  Clinicaltrials.gov  NCT02785250 (ONC-DPX-Survivac-06) A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer S. Ghamande Sandra Wall Ovarian Cancer Ib
TESARO 4010-01-001   ClinicalTrials.gov   NCT02715284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Kelly Jenkins Advanced solid tumors I

Phase I/II

ADXS001-04      ClinicalTrials.gov
NCT02291055
Phase 1-2 Study of MEDI4736 Alone or In Combination With ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Metastatic Head & Neck Cance S. Ghamande Renee Townsend Phase 1: Cervical Cancer,  HPV+ Head & Neck Cancer
Phase 2: Cervical Cancer
I/II 
C-550-01 ClinicalTrials.gov:  NCT03495882 A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors Protocol Type: Treatment S. Ghamande Donna Wheatley Advanced Solid Tumors I/II
C-700-01  ClinicalTrials.gov:  NCT01772004 A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer S. Ghamande Renee Townsend Cervical Cancer I/II
CC-16047   ClinicalTrials.gov   NCT02834052 A phase I/II trial of pembrolizumab (MK-3475) and poly-ICLC in patients with metastatic mismatch repair-proficient (MRP) colon cancer A. Nayak Kelly Jenkins Phase 1: All solid tumors, following at least one therapy Phase 2: Mismatch Repair Proficient “MRP” (includes microsatellite stable [MSS] and MSI-low) colon cancer that has progressed following at least two lines of therapy I/II
GSK 201973  ClinicalTrials.gov  NCT02964507 A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Fulvestrant in Subjects with ER+ Breast Cancer H. Boppidi Sandra Wall ER+ Breast Cancer I/II

IMDZ-G142  ClinicalTrials.gov:  NCT02501473

 Phase 1/2 Study of Intratumoral G100 Therapy in Patients With or Without Pembrolizumab in Patients Wuth Follicular Non-Hodgkin's Lymphoma  L. Bryan Connie Edwards  Non-Hodgkin's Lymphoma  I/II
INCB-39110-206  ClinicalTrials.gov     NCT02760485 An Open Label Phase 1/2 Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma   L. Bryan Connie Edwards Diffuse Large B-Cell Lymphoma I/II 
NLG-2106 ClinicalTrials.gov NCT02835729 A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) J. Pantin Crystal Durden Acute Myeloid Leukemia (AML) I/II

NRG-GY007  ClinicalTrials.gov   NCT02713386

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Protocol Type: Treatment S. Ghamande Melissa James Ovarian, Fallopian Tube, or Peritoneal Cancer I/II

VT3996-201 ClinicalTrials.gov  NCT03397706

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Protocol Type: Treatment L. Bryan Sandra Wall  Epstein-Barr Virus Associated Lymphoid Malignancies Ib/II

Closed for New Patient Enrollment, Open for Current Patients

EMR 100070-001 A Phase 1, Open-Lable, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indicators (PI: Khleif)
GO29753 (formerly NLG-9191) A Phase 1 Study of GDC-0919 for Adult Patients with Recurrent Advanced Solid Tumors (PI: Khleif)
MEDI4736-1108 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors (PI: Khleif)
NLG-2102 A Phase 1/2 Study of the Combination of 1-Methyl-D-Tryptophan (Indoximod) and Temozolomide for Adults Patients with Temozolomide-Refractory Primary Malignant Brain Tumors (PI: Hao)
NLG-2103 A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Ipilimumab for Adult Patients with Advanced or Metastatic Melanoma (PI: Parikh)